ASCO 2015 Highlights

Dose De-Escalation in Fit, Older Patients with CLL: Balancing Efficacy, Safety, and Tolerability

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Update from the RESONATE Trial: Ibrutinib versus Ofatumumab in Relapsed/Refractory CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

The Benefit of Adding Rituximab to Ibrutinib in Relapsed/Refractory CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Interim Analysis of the PROLONG Study: Ofatumumab Maintenance Therapy in Patients with Relapsed CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ibrutinib Salvage in Relapsed CLL After Allogeneic Transplantation

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Final Results from the CLL20 Study: Alemtuzumab plus Dexamethasone in Very High–Risk Patients with CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ibrutinib-Based Regimens for Patients with Relapsed/Refractory CLL: Impact of Complex Karyotype

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Frontline Chemoimmunotherapy with Fludarabine/Cyclophosphamide/Rituximab versus Bendamustine/Rituximab in Advanced CLL: Final Analysis of the CLL10 Study

Conference Correspondent

Ibrutinib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Safety and Efficacy of Ibrutinib plus Rituximab in Relapsed Mantle-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent

Page 207 of 329